Emil Hagström


Affiliation: Uppsala University Hospital
Country: Sweden


  1. Hagström E, Michaelsson K, Melhus H, Hansen T, Ahlstrom H, Johansson L, et al. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts. Arterioscler Thromb Vasc Biol. 2014;34:1567-73 pubmed publisher
    ..Our data confirm and extend previous studies supporting a role for PTH in the development of atherosclerotic disease. ..
  2. Hagström E, Hellman P, Larsson T, Ingelsson E, Berglund L, Sundstrom J, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765-71 pubmed publisher
    ..Further studies are warranted to evaluate the clinical implications of measuring PTH in cardiovascular risk prediction and to elucidate whether PTH is a modifiable risk factor. ..
  3. Hagström E, Ahlström T, Ärnlöv J, Larsson A, Melhus H, Hellman P, et al. Parathyroid hormone and calcium are independently associated with subclinical vascular disease in a community-based cohort. Atherosclerosis. 2015;238:420-6 pubmed publisher
    ..The findings indicate a possible link between the vasculature and mineral metabolism. ..
  4. Hagström E, James S, Bertilsson M, Becker R, Himmelmann A, Husted S, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J. 2016;37:1325-33 pubmed publisher
    ..www.clinicaltrials.gov; NCT00391872. ..
  5. Hagström E, Held C, Stewart R, Aylward P, Budaj A, Cannon C, et al. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clin Chem. 2017;63:325-333 pubmed publisher
    ..Information on GDF-15, therefore, might be helpful when assessing the risk of adverse outcomes in patients with stable CHD. ClinicalTrials.gov Identifier: NCT00799903. ..